SCHEMBL26494053

SCHEMBL26494053

C[C@H](CC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4CCCC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.80

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 13/20 0.80
▸ NR1H4 Q96RI1 5/20 0.80
▸ MEN1 O00255 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ ABCB11 O95342 2/20 0.62
▸ SLC10A2 Q12908 2/20 0.62
▸ LMNA P02545 1/20 0.62
▸ CYP2C19 P33261 1/20 0.62
▸ CHRM2 P08172 1/20 0.62
▸ ADRA2A P08913 1/20 0.62
▸ ADRA1A P35348 1/20 0.62
▸ TDP1 Q9NUW8 1/20 0.62
▸ ENPP2 Q13822 1/20 0.62
▸ SLC10A1 Q14973 1/20 0.62
▸ CISD1 Q9NZ45 1/20 0.62
▸ CYP3A4 P08684 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10074118 0.89 GPBAR1 (1.00) GPBAR1NR1H4MEN1KMT2AABCB11
SCHEMBL22627010 0.89 GPBAR1 (1.00) GPBAR1NR1H4MEN1KMT2AABCB11
SCHEMBL22626977 0.89 GPBAR1 (1.00) GPBAR1NR1H4MEN1KMT2AABCB11
SCHEMBL24897216 0.89 GPBAR1 (1.00) GPBAR1NR1H4MEN1KMT2AABCB11
SCHEMBL24437428 0.89 GPBAR1 (1.00) GPBAR1NR1H4MEN1KMT2AABCB11
SCHEMBL23483146 0.89 GPBAR1 (1.00) GPBAR1NR1H4MEN1KMT2AABCB11
SCHEMBL23483076 0.89 GPBAR1 (1.00) GPBAR1NR1H4MEN1KMT2AABCB11
SCHEMBL24404377 0.89 GPBAR1 (1.00) GPBAR1NR1H4MEN1KMT2AABCB11
SCHEMBL21710850 0.89 GPBAR1 (1.00) GPBAR1NR1H4MEN1KMT2AABCB11
SCHEMBL11063589 0.89 GPBAR1 (1.00) GPBAR1NR1H4MEN1KMT2AABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135729-A1 COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF CHENGDU BIOBEL COMPANY LIMITED (CN) 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135729-A1 COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF CASP9, CLPP, CASP1 GPBAR1 567/4885NR1H4 896/4885MEN1 3578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback